Clinical value of infusion gemcitabine via artery port and catheter system for 37 cases with ad-vanced panceratic cancer / 中国癌症杂志

ABSTRACT

Purpose:To investigate the efficacy of infusion gemcitabine via artery port and catheter system (PCS) for advanced pancreatic cancer.Methods:57 cases advanced pancreatic cancer proved by pathology were implanted Implantofix PCS.The number of ports implanted subcutaneously in inferior right abdomen and subcutanceusly in inferior chest was 48 and 9 cases respectively.The first total does in experience group was gemcitabine 3.0,5-FU 3.0,IL-2 6 million u via three times infusion.Results:The overall implanted successful rates was 100% and indwelling catheter tip dislocation rate was 0. Two PCS were pulled out in 2 fat old female patients because of bad wound healing after two months.In the experimental and control group according to the standard of clinical benefit-responces were 37 and 20 respectively.The obvious improve- ment in pain in experimental and control group was 27.2% and 4.8%,respectively.The duration of clinical benefit-re- sponces were 18 weeks in experimental groups,13 weeks in control group.The midian survival in experimental group was 6.25 months,4.41 months in control group.The 6-,9-,12-months survival rates in experimental group were 46%,24%, 18% more thans 31%,6% and 2% in control group.Conclusions:Infusion gemcitabine via artery PCS can not only relieve pain,prolong survival rate but also provides a long-term intra-arterial chemotherapy and effctive access for advanced pancre- atic cancer.